The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Capillary leak syndrome (CLS)
Publications
Lagan J, Naish JH, Fortune C, Campbell C, Chow S, Pillai M, Bradley J, Francis L, Clark D, Macnab A, Nucifora G, Dobson R, Schelbert EB, Schmitt M, Hawkins R, Miller CA
Acute and Chronic Cardiopulmonary Effects of High Dose Interleukin-2 Therapy: An Observational Magnetic Resonance Imaging Study.
Diagnostics (Basel, Switzerland) 2022 May 30;12; — 2022 May 30
Clinical effects and toxicity of interleukin-2 in patients with cancer.
Cancer 1986 Dec 15;58;2764-72 — 1986 Dec 15 — 2764-72
Cardiopulmonary toxicity of adoptive immunotherapy.
The American journal of the medical sciences 1988 Dec;296;406-12 — 1988 Dec — 406-12
Lee RE, Lotze MT, Skibber JM, Tucker E, Bonow RO, Ognibene FP, Carrasquillo JA, Shelhamer JH, Parrillo JE, Rosenberg SA
Cardiorespiratory effects of immunotherapy with interleukin-2.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989 Jan;7;7-20 — 1989 Jan — 7-20
Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer.
Blood 1991 Sep 15;78;1538-44 — 1991 Sep 15 — 1538-44
[Radiologic characteristics of the thorax during therapy with interleukin-2].
La Radiologia medica 1992 Oct;84;368-71 — 1992 Oct — 368-71